
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
Subscribe
In this first session, the experts discuss their standard approach when using ranibizumab (Lucentis, Genentech) to treat their patients with age-related macular degeneration.
Participants include:
Return to
Return to




